Novartis submits NDA for ASM 981

Novartis (NVS; SWX:NOVN) submitted an NDA to the FDA for its ASM 981 non-steroid ascomycin derivative 1 percent cream, to treat atopic dermatitis (eczema). The compound is a selective inhibitor of inf...